

IFW  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**



**Applicant(s):** Michl et al.

**Examiner:** Unassigned

**Serial No.:** 10/542,239

**Group:** Unassigned

**Filed:** March 3, 2006

**Docket:** 1181-8 PCT US

**For:** **PANCREATIC CANCER  
ASSOCIATED ANTIGEN,  
ANTIBODY THERETO, AND  
DIAGNOSTIC AND TREATMENT  
METHODS**

**Dated:** December 21, 2006

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to Applicants duty of disclosure, the information listed in the attached Form PTO-1449 is brought to the attention of the Examiner. Copies of the listed publications are submitted herewith.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art. The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 21, 2006.

Dated: December 21, 2006

  
Ann R. Pokalsky

assist in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Applicants previously submitted an Information Disclosure Statement in this case. The Information Disclosure Statement submitted herewith lists references cited in a Supplementary International Search Report issued in a counterpart International Application No. PCT/US04/1196 received from the International Searching Authority, (dated October 30, 2006). Applicants are submitting copies of the references, together with a copy of the Supplementary Search Report.

Inasmuch as this Information Disclosure Statement is being filed prior to the mailing of a first office action on the merits, no fee is due.


Nevertheless, please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 04-1121. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No. 04-1121 therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to be patentably

distinguishable over the prior art and to be in condition for allowance. Early and favorable consideration of the case is respectfully requested.

DILWORTH & BARRESE, LLP  
333 Earle Ovington Boulevard  
Uniondale, New York 11553  
Tel. No. (516) 228-8484  
Fax No. (516) 228-8516  
ARP/ml

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Ann R. Pokalsky". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

Ann R. Pokalsky  
Registration No.: 34,697  
Attorney for Applicants

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
1181-8 PCT USSERIAL NO.  
10/542,239APPLICANTS  
Michl et al.FILING DATE  
March 3, 2006GROUP ART UNIT  
UnassignedINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2002/0098581 A1	07/25/2002	Glassy et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Hannan et al. (November 2002), "PaCa-Agl: Isolation and Cloning of a Marker for Pancreatic Cancer", *Molecular Biology of the Cell*, Vol. 13 suppl., page 137a.Hannan et al. (September 2003), "Immunotherapeutic Application of Novel Pancreatic Cancer-Specific Tumor Marker PaCa-Agl" *EJC Supplements*, 1(5):S19.Hannan et al. (July 2003) "PaCa-Agl, "A candidate Pancreatic Cancer (PaCa) Specific Tumor Marker", *Proceedings of the American Assoc. for Cancer Res. Annual Meeting*", 44:360.Bradu et al. (November 1998) "Identification of Transformation-Associated Antigen Induced by the Tobacco Smoke-Specific Carcinogen NNK in Pancreatic Acinar Cells BMRPA.430", *Mol Bio of the Cell*, 9 suppl., page 490A.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1181-8 PCT US	SERIAL NO. 10/542,239
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANTS Michl et al.	
		FILING DATE March 3, 2006	GROUP ART UNIT Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

			Raffaniello et al. (May 1998) "Protein Kinase C Isoform Expression and Function in Transformed and Non-Transformed Pancreatic Acinar Cell Lines" <i>Biochemical and Biophysical Research Communications</i> , 246:1 166-171.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.